REG - Novacyt S.A. - Liquidity Agreement and Total Voting Rights

Novacyt SAAnnouncement

01/09/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230901:nRSA1461La&default-theme=true

RNS Number : 1461L  Novacyt S.A.  01 September 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Liquidity Agreement Monthly Update and Total Voting Rights

 

Paris, France and Eastleigh, UK - 1 September 2023 - Novacyt (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces its monthly update in relation to ordinary shares
traded under its ongoing liquidity agreement with Invest Securities SA (the
"Liquidity Agreement"). The Liquidity Agreement is governed by French law and
is further summarised below.

 

During the period from 1 August to 31 August 2023, Invest Securities purchased
204,857 ordinary shares at a maximum price of €0.93 and a minimum price of
€0.63 and sold 203,023 ordinary shares at a maximum price of €0.95 and a
minimum price of €0.67 under the Liquidity Agreement. The total number of
ordinary shares in the Company, which are held in treasury as at close of
business on 31 August 2023, is 49,143.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 70,626,248. This figure
may be used by shareholders as the denominator for calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not subject to the
disclosure guidance and transparency rules made by the Financial Conduct
Authority under Part VI of FSMA.

 

Contacts

 

 Novacyt SA                                                +44 (0) 23 8074 8830
 James Wakefield, Non-Executive Chairman

 James McCarthy, Acting Chief Executive Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                           +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Numis (Joint Broker)                                                                    +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Jack McLaren

 Allegra Finance (French Listing Sponsor)                                                +33 (1) 42 22 10 10
 Rémi Durgetto / Yannick Petit                                                            r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
                                                                                         y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                           +44 (0)20 7933 8780

 Stephanie Cuthbert / Anna Dunphy / Phillip Marriage       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and
Eastleigh, UK, and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

Further information on the Liquidity Agreement

 

On 12 September 2016, the Company and Invest Securities entered into the
Liquidity Agreement pursuant to which Invest Securities provides liquidity
services in relation to the ordinary shares to the Company. Invest Securities
may purchase ordinary shares on behalf of the Company under the agreement,
subject to approval from Shareholders as to the price at which ordinary shares
can be brought back and the aggregate amount that the Company may provide to
Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 20 July
2022 for the purchase of ordinary shares by Invest Securities under the
agreement at a maximum purchase price per ordinary shares of €12.00 for an
aggregate maximum purchase price of €200,000 and for 18 months from the date
of the approval. Under the agreement, Invest Securities must act completely
independently of the Company and the Company must not communicate with the
employees of Invest Securities who are responsible for performing the
agreement. Invest Securities is paid €10,000 per annum for its services
under the liquidity agreement. The agreement has an initial term of two years,
with a rolling extension of one year thereafter. The agreement can be
terminated by either party at the end of each such period subject to two
months' prior notice. The Liquidity Agreement is governed by French law.
Ordinary shares purchased by Invest Securities are either cancelled or held as
treasury shares (which are non-voting and do not rank for dividends).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBFLFBXKLEBBV